1. Orlife introduces the mature CARTISTEM stem cell drug preparation technology, standard stem cell drug production and quality management system of Korea MEDIPOST.
2. CARTISTEM is an allogeneic source (donors and recipients are not the same), and blood cord can be produced on a large scale and easier to achieve industrial scale than self homologous.
3. Through the company's proprietary titer tagging system, Orlife established a unified production standard, and ensured the safety and effectiveness of CARTISTEM.4. CARTISTEM, contain Multipotential human umbilical cord blood mesenchymal stem cells, and allograft rejection does not occur immunologic rejection action.